April 2007
BioWorld Today;4/5/2007, Vol. 18 Issue 66, p3
The article presents news briefs on biotechnology industry in the U.S. The holders of Chromos Molecular Systems Incorporated's convertible, secured bridge loan have demanded repayment of the principal and interest. CytoGenix Inc. has completed a pilot study for its synDNA vaccine for human against the avian influenza virus. Nanogen Inc. has won a U.S. Government Service Administration contract for its NanoChip 400 microarray instrument and reagents.


Related Articles

  • DNA Chip Technology: A Promising Future for Diagnosing Disease. Webb, Marion // San Diego Business Journal;07/03/2000, Vol. 21 Issue 27, p1 

    Features San Diego, California-based Nanogen Inc.'s DNA chip technology. Use of the chips to identify and analyze genes; Value of the global market for bioassays in genomic research; Key features and functions of Nanogen's technology.

  • Nanogen Lowers 2002 Forecast Due to Delayed Shipment. Webb, Marion // San Diego Business Journal;8/5/2002, Vol. 23 Issue 31, p3 

    Reports that the San Diego, California-based gene chip maker Nanogen Inc. has lowered its 2002 revenue forecast due to a delay in the planned June 2002 shipment of its cystic fibrosis test to additional beta-test sites. Change in revenue forecast; Revalidation of the fibrosis test in a hospital.

  • Viagene, Nanogen find new revenue sources. Fikes, Bradley J. // San Diego Business Journal;5/1/95, Vol. 16 Issue 18, p3 

    Assesses the financial performance of biotechnology companies in California. Proposed takeover of Viagene Inc. by Chiron Corp.; Price of Viagene's stocks; Purchase and acquisition moves by large pharmaceutical firms; Funders for Nanogen Inc.; Competition to make microchip diagnostic products.

  • XENCOR LICENSES CHRONOS' ACE TO GENERATE PDA CELL LINES.  // Worldwide Biotech;Nov2003, Vol. 15 Issue 11, p8 

    Reports on the entry of Chromos Molecular Systems and Xencor into a non-exclusive research license agreement to develop cell lines that express Xencor's monoclonal antibodies as of November 2003.

  • Germline transmission of artificial chromosome. Dove, Alan // Nature Biotechnology;Dec99, Vol. 17 Issue 12, p1149 

    Focuses on the release of a satellite DNA-based artificial chromosome (SAT-DAC) by a biotechnology company Chromos Molecular Systems Inc. Use of the chromosome in the insertion of any gene into mammalian cells without the risk of disrupting other genes; Plans of the company regarding use of the...

  • Unlocking genetic secrets. Mangelsdorf, Martha E.; Bianchi, Alessandra // Inc.;Feb94, Vol. 16 Issue 2, p29 

    Profiles three start-ups that have jumped into the human genome-related market, hoping to find genes that either cause or predispose people to any number of diseases. Millennium Pharmaceuticals, Cambridge, Mass., founded by Mark Levin, targets Type II diabetes and obesity; Nanogen, San Diego,...

  • Pass it on. Coghlan, Andy // New Scientist;07/08/2000, Vol. 167 Issue 2246, p7 

    Describes how artificial chromosomes can pass from one generation to the next. Description of an experiment by Deborah Co of Chromos Molecular Systems in Burnaby, British Columbia to implant altered chromosomes into mice; Outlook for future experiments on protein-producing genes; Chromosomes...

  • OTHER NEWS TO NOTE.  // BioWorld Today;5/11/2007, Vol. 18 Issue 92, p5 

    This section presents news briefs related to the biotechnology industry across the world. Atrium Biotechnologies Inc. in Quebec, changed its name to Atrium Innovations Inc. CytoGenix Inc. in Houston, Texas, and Eurogentec SA in Liege, Belgium, executed a letter of intent regarding the...

  • Deals roundup.  // Diagnostics & Imaging Week;7/19/2007, Vol. 10 Issue 29, p5 

    This section offers news briefs related to deals in the biotechnology industry. SensiGen has acquired an option from the University of Michigan-Ann Arbor to exclusively license a set of epigenetic biomakers for early detection and monitoring of Lupus. Nanogen has acquired the rights to genetic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics